

IN THE CLAIMS

Please amend the claims as shown on the marked-up copy following this amendment to read as follows.

Sub *AB32*

3. (Amended) The agent of claim 1, wherein the macrolide compound is FK506.
4. (Amended) The agent of claim 1, which is in the form of a preparation for local administration to the eye.
5. (Amended) The agent of claim 1, which aims at improving tear film breakup time.

REMARKS

Claims 1-7 are active in the present application. Claims 2-5 have been amended to remove multiple dependencies. The specification has been amended to correct a typographical or clerical error. No new matter is believed to have been added. An action on the merits and allowance of claims is solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518



22850

(703) 413-3000
NFO/DJP/smi
I:\atty\SUKOS\215246US-pr.wpd